Braidwell LP Buys 367,663 Shares of Celcuity Inc. (NASDAQ:CELC)

Braidwell LP grew its stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 71.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 884,306 shares of the company's stock after acquiring an additional 367,663 shares during the quarter. Braidwell LP owned about 2.39% of Celcuity worth $13,185,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of CELC. Samlyn Capital LLC boosted its stake in Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock valued at $21,735,000 after purchasing an additional 637,190 shares during the last quarter. Driehaus Capital Management LLC boosted its position in shares of Celcuity by 62.3% during the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company's stock valued at $3,351,000 after buying an additional 78,525 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new stake in shares of Celcuity during the second quarter valued at $1,065,000. Hennion & Walsh Asset Management Inc. bought a new stake in Celcuity in the 2nd quarter worth about $888,000. Finally, Point72 Asset Management L.P. bought a new position in Celcuity during the 2nd quarter valued at about $951,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Stock Performance

Celcuity stock traded down $0.05 during trading on Friday, reaching $12.80. The company had a trading volume of 140,762 shares, compared to its average volume of 279,118. The firm has a market capitalization of $475.26 million, a price-to-earnings ratio of -4.90 and a beta of 0.76. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 52 week low of $11.51 and a 52 week high of $22.19. The firm's 50-day simple moving average is $14.70 and its 200 day simple moving average is $15.74.

Wall Street Analysts Forecast Growth

CELC has been the subject of several research reports. Needham & Company LLC reissued a "buy" rating and set a $23.00 price objective on shares of Celcuity in a report on Friday, November 15th. HC Wainwright reiterated a "buy" rating and set a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Stifel Nicolaus raised their price target on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Finally, Lifesci Capital assumed coverage on Celcuity in a research report on Monday, August 26th. They set an "outperform" rating and a $27.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.